<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901663</url>
  </required_header>
  <id_info>
    <org_study_id>BAD-VPZ-001</org_study_id>
    <nct_id>NCT04901663</nct_id>
  </id_info>
  <brief_title>Vonoprazan in Helicobacter Pylori Treatment an RCT</brief_title>
  <official_title>Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT for comparison of Standard Triple therapy (Omeprazole+Amoxil+Clarithromycin) for H Pylori&#xD;
      erradication with Vonoprazan+Amoxil dual therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE To compare the efficacy of Vonoprazan based dual treatment versus PPI based&#xD;
      treatment for the eradication of Helicobacter pylori infection.&#xD;
&#xD;
      OPERATIONAL DEFINITION&#xD;
&#xD;
      Helicobacter Pylori infection: Hp infection will be labelled by any one of following&#xD;
      investigation:&#xD;
&#xD;
        -  Helicobacter Pylori Stool Antigen&#xD;
&#xD;
        -  Histopathology on Giemsa Stain&#xD;
&#xD;
      MATERIAL AND METHODS:&#xD;
&#xD;
      Study Design: Randomized control trial. Setting: This study will be conducted in the Medical&#xD;
      OPD and Medical Unit 1 of Dr. Ruth K.M. Pfau, Civil Hospital Karachi affiliated with Dow&#xD;
      University of Health Sciences&#xD;
&#xD;
      DATA COLLECTION PROCEDURE:&#xD;
&#xD;
      All patients presenting to the OPD or Medical Unit 1 of Dr. Ruth KM Pfau, Civil Hospital&#xD;
      Karachi and fulfilling the inclusion criteria will be included after taking informed consent.&#xD;
&#xD;
      The participants will be randomly allocated to 2 groups with help of random number table and&#xD;
      will be treated for 2 weeks.&#xD;
&#xD;
      Group A: will be given:&#xD;
&#xD;
      Capsule Amoxicillin 1 gm twice daily Tablet Clarithromycin 500 mg twice a day Capsule&#xD;
      Omeprazole 20 mg twice a day&#xD;
&#xD;
      Group B will be given:&#xD;
&#xD;
      Capsule Amoxicillin 1 gm twice daily Tablet Vonoprazan 20 mg twice a day Confirmation of Hp&#xD;
      eradication will be done by stool Hp antigen test 4 weeks after completion of treatment.&#xD;
&#xD;
      DATA ANALYSIS Data will be stratified according to age &amp; gender. Frequency of gender &amp; mean&#xD;
      (SD) of age will be compared between groups using Pearson's Chi-square test and Student's&#xD;
      t-test respectively. Frequency of Hp eradication between two groups will be compared using&#xD;
      Pearson's chi-square test. A p value &lt; .05 will be taken as significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter Pylori Eradication</measure>
    <time_frame>4 weeks</time_frame>
    <description>Stool Heliobacter Pylori Antigen = Negative</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Omeprazole Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole 20 mg BD Amoxicillin 1000 mg BD Clarithromycin 500 mg BD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vonoprazan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan 20 mg BD Amoxicillin 1000 mg BD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole 20 MG Capsule; Amoxicillin 1000 MG; Clarithromycin 500 MG</intervention_name>
    <description>Orally twice daily for 2 weeks</description>
    <arm_group_label>Omeprazole Group</arm_group_label>
    <other_name>Omeprazole Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan 20 MG; Amoxicillin 1000 MG</intervention_name>
    <description>Orally twice daily for 2 weeks</description>
    <arm_group_label>Vonoprazan Group</arm_group_label>
    <other_name>Vonoprazan Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Helicobacter Pylori Positive by any one of following:&#xD;
&#xD;
        Histopathology by Giemsa Stain Stool Antigen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Previous surgery of the stomach such as partial gastrectomy.&#xD;
&#xD;
               -  Allergy to any of the antibiotics used in the study.&#xD;
&#xD;
               -  Intake of antibiotics, PPIs, corticosteroids, or nonsteroidal anti-inflammatory&#xD;
                  drugs within the last 2 weeks.&#xD;
&#xD;
               -  Pregnant or lactating females.&#xD;
&#xD;
               -  Alcohol abuse or drug addiction.&#xD;
&#xD;
               -  Severe neurological or psychiatric disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bader F Zuberi, FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dow University of Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Ruth KM Pfau Civil Hospital Karachi</name>
      <address>
        <city>Karachi</city>
        <state>Sindh</state>
        <zip>74400</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019 Apr 5;10:316. doi: 10.3389/fphar.2019.00316. eCollection 2019. Review.</citation>
    <PMID>31024299</PMID>
  </results_reference>
  <results_reference>
    <citation>Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27. Review.</citation>
    <PMID>28456631</PMID>
  </results_reference>
  <results_reference>
    <citation>Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017 Sep;22 Suppl 1. doi: 10.1111/hel.12403. Review.</citation>
    <PMID>28891138</PMID>
  </results_reference>
  <results_reference>
    <citation>Crowe SE. Helicobacter pylori Infection. N Engl J Med. 2019 Mar 21;380(12):1158-1165. doi: 10.1056/NEJMcp1710945. Review.</citation>
    <PMID>30893536</PMID>
  </results_reference>
  <results_reference>
    <citation>Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol. 2018 Dec;41(10):654-662. doi: 10.1016/j.gastrohep.2018.06.014. Epub 2018 Sep 1. English, Spanish.</citation>
    <PMID>30180998</PMID>
  </results_reference>
  <results_reference>
    <citation>Ke H, Li J, Lu B, Yang C, Wang J, Wang Z, Liu L, Chen Y. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter. 2021 Feb;26(1):e12768. doi: 10.1111/hel.12768. Epub 2020 Oct 21.</citation>
    <PMID>33089598</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang YC, Chen YP, Ho CY, Liu TW, Chu CH, Wang HY, Liou TC. The Impact of Gastric Juice pH on the Intraluminal Therapy for Helicobacter pylori Infection. J Clin Med. 2020 Jun 14;9(6). pii: E1852. doi: 10.3390/jcm9061852.</citation>
    <PMID>32545856</PMID>
  </results_reference>
  <results_reference>
    <citation>Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016 Sep;65(9):1439-46. doi: 10.1136/gutjnl-2015-311304. Epub 2016 Mar 2.</citation>
    <PMID>26935876</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):550-555.</citation>
    <PMID>27867688</PMID>
  </results_reference>
  <results_reference>
    <citation>Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018 Mar;53(3):354-361. doi: 10.1007/s00535-017-1407-1. Epub 2017 Nov 14. Review.</citation>
    <PMID>29138921</PMID>
  </results_reference>
  <results_reference>
    <citation>Kato M, Ota H, Okuda M, Kikuchi S, Satoh K, Shimoyama T, Suzuki H, Handa O, Furuta T, Mabe K, Murakami K, Sugiyama T, Uemura N, Takahashi S. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019 Aug;24(4):e12597. doi: 10.1111/hel.12597. Epub 2019 May 20.</citation>
    <PMID>31111585</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dow University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Bader Faiyaz Zuberi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>Vonoprazan</keyword>
  <keyword>potassium-competitive acid inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

